The Government Is Finally Studying How People Actually Use Psychedelics. The Bad Trips Are the Point.

Most of what you have read about psilocybin and MDMA comes from people who almost never look like the people actually taking them. Clinical trial volunteers are screened hard for psychosis risk, recent substance problems and messy medication lists. They take a measured dose in a quiet room with two trained therapists and a playlist. Meanwhile the real world, the one you may live in, is a bag from a friend, a retreat with a slick website, a ketamine night that turned into a ketamine month. The science and the street have been describing two different drugs.

That gap just got federal money. UC San Francisco announced that its CANOPY study, led by neurologist Robin Carhart-Harris, will follow as many as 3,000 people around the world who already plan to take psychedelics at home, at organized retreats and elsewhere, tracking mood and well-being before, after, and for up to six months. Researchers will not supply drugs or tell anyone what to take; the substances include psilocybin, LSD, ayahuasca, ibogaine, MDMA and ketamine. CANOPY received up to $1.4 million of three UCSF awards totaling up to $8.5 million from ARPA-H, the federal health research agency.

The most useful thing CANOPY can produce is an honest count of who gets hurt, not another headline about who gets healed.

Participants who can travel to San Francisco also get brain imaging, EEG, blood work and wearable sensors, according to SFist. Carhart-Harris framed the goal as learning “not just whether psychedelics can be beneficial, but for whom, under what circumstances, and why.” Read that sentence from the recovery side and the “for whom” is the whole ballgame. People with a history of psychosis, people whose ketamine use slid from medicine into dependence, people who foraged the wrong mushroom, as we covered in our spotlight on psilocybin look-alikes: those are exactly the people trials exclude, and exactly the people who show up in an ER or a detox. With psilocybin applications now sitting at the FDA, the public conversation is about to be dominated by the cleanest data that exists. Real-world data is how it gets corrected.

There are fair worries. A self-selected cohort of planned users skews toward people having good experiences, and six months is short for anyone whose trouble builds slowly. But if you are in recovery and wondering whether the psychedelic hype applies to you, the most protective thing anyone can give you is evidence drawn from people like you, not from a screened volunteer with a perfect chart. For providers, the move this week is simpler than any study: ask patients directly whether they have used or plan to use psychedelics, at home or at a retreat, and treat the answer as clinical information, not a confession. More lives on our psychedelics pillar.

If the study is built well, its bad-trip data will save more people than its breakthroughs.